Aceto will acquire A&C Bio Buffer, including the company’s custom buffer and chemical blend portfolio.
Aceto, a provider of specialty materials, announced its acquisition of A&C Bio Buffer, a good manufacturing practices (GMP) manufacturer of custom buffer and chemical blend products used in the manufacturing of biopharmaceutical drug products, in an Oct. 12, 2021, press release. At A&C Bio Buffer’s ISO 9001:2015-certified facility in Limerick, Ireland, the company manufactures more than 50 products, including biological buffers, process solutions, cleaning solutions, and water for injection.
“A&C Bio Buffer is a natural add-on to our acquisition of A&C and aligns with our commitments to the biopharmaceutical space,” said Gilles Cottier, CEO of Aceto, in the press release. “It is a nimble, highly customer-centric organization serving some of the top biopharmaceutical manufacturers in Europe. Its rapid growth reflects a reputation for service and quality, which recently led to its key role in the raw material supply chain for COVID-19 vaccines. A&C Bio Buffer enhances our growing European manufacturing footprint and commercial presence. We believe the shared lineage reflected in A&C Bio Buffer’s skills, culture and customer focus will further support our evolution as a leading supplier of critical raw materials in the life sciences sector.”
Earlier this year, Aceto also acquired A&C, a global manufacturer of GMP specialty excipients and custom process solutions. According to Aceto’s press release, the company will continue to support A&C BioBuffer’s manufacturing facilities and offices in Ireland. However, financial terms were not disclosed.
Source: Aceto
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.